DUBLIN, May 15, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced results from two late-breaking clinical trials presented virtually at the 2020 Society for Cardiovascular Angiography ...
Medtronic delivered new data from two clinical trials evaluating the long-term safety and shorter-term performance of its transcatheter pulmonary valve replacement therapies for children with ...
For years, innovations in the treatment of pulmonary valve regurgitation have relied on invasive surgical treatments—until now. A device from Medtronic that takes a minimally invasive approach to ...
Harmony™ Transcatheter Pulmonary Valve is First Minimally Invasive Alternative for Patients with Severe Pulmonary Regurgitation Who Have a Native or Surgically-Repaired Right Ventricular Outflow Tract ...
WASHINGTON (Reuters) - A non-surgically implanted heart valve meant to delay open heart surgery in children with congenital heart defects worked well for all but a few patients during a year of follow ...
Medtronic's Harmony transcatheter pulmonary valve (TPV) was approved Friday for treatment of severe pulmonary valve regurgitation with a native or surgically repaired right ventricular outflow tract ...
Medtronic plc has received the first FDA approval for a transcatheter pulmonary valve to treat patients whose bioprosthetic pulmonary heart valves have failed. For these congenital heart disease ...
Milestone Results Presented as Late-Breaking Clinical Science at SCAI 2020 DUBLIN, May 15, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced results from two late-breaking clinical ...
WASHINGTON, March 30 (Reuters) - A non-surgically implanted heart valve meant to delay open heart surgery in children with congenital heart defects worked well for all but a few patients during a year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results